Search

Retatrutide and Tirzepatide pre-blended for advanced metabolic protocols. Dual and triple agonist coverage in one vial.

Triple incretin agonist activating GLP-1, GIP, and glucagon receptors. The most comprehensive metabolic receptor coverage in a single peptide.

Dual GIP/GLP-1 agonist for advanced metabolic and weight-management protocols. One of the most studied incretin peptides in modern metabolic science.

Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.

ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.